RheumaGen Raises $15 Million Series A, Secures Strategic Investment to Advance HLA Gene‑Editing Therapies
RheumaGen, a biotechnology company pioneering a new class of cell and gene therapies aimed at curing major autoimmune diseases, has secured $15 million in Series A financing to advance its breakthrough human leukocyte antigen (HLA) gene‑editing platform toward clinical evaluation. The funding will support RheumaGen’s lead therapeutic program, RG0401, as it prepares for Phase I clinical trials slated for 2026 in treatment‑resistant or refractory rheumatoid arthritis (RA), a population with significant unmet medical need.
Founded with the mission of tackling autoimmune diseases at their underlying source rather than merely treating symptoms, RheumaGen is focused on editing the “immune gene” HLA so that patients’ immune systems no longer mistakenly attack healthy tissue. By precisely modifying HLA alleles associated with disease susceptibility, the company believes its therapies could permanently halt autoimmune responses and offer curative potential for conditions such as rheumatoid arthritis, multiple sclerosis, type 1 diabetes, and ankylosing spondylitis.
The Series A round was co‑led by SPRIM Global Investments and William Taylor Nominees, underscoring institutional confidence in the company’s scientific foundation and strategic vision. These investors bring experience in supporting high‑impact life sciences ventures with the potential to reshape therapeutic paradigms. RheumaGen’s leadership has emphasized that this capital infusion will enable the company to accelerate its clinical development efforts and expand its pipeline across multiple autoimmune targets.
Richard Freed, CEO and Co‑Founder of RheumaGen, said the company’s focus on curative rather than incremental treatments stems from a deep commitment to improving patient outcomes. He emphasized that the Series A financing will help RheumaGen progress its clinical programs and bring transformative therapies closer to patients suffering from debilitating autoimmune diseases. The company’s scientific leadership blends immunology, histocompatibility expertise, and cell and gene therapy experience to pursue treatments that could fundamentally shift how autoimmunity is addressed.
RheumaGen’s lead candidate, RG0401, is being developed to treat the 10‑20 percent of rheumatoid arthritis patients who are refractory to existing therapies — a group that currently lacks effective options. The therapy works by precisely editing HLA DNA markers to mirror those found in individuals naturally resistant to RA, effectively preventing harmful immune activation that drives chronic inflammation and tissue degradation. The company expects to complete IND‑enabling studies and initiate Phase I trials in 2026 as part of its goal to demonstrate safety and initial efficacy in human subjects.
In addition to its RA program, RheumaGen is building out its pipeline to address other autoimmune diseases in which HLA alleles play a significant role in disease development. Programs targeting conditions such as multiple sclerosis, type 1 diabetes, and ankylosing spondylitis are in various stages of preclinical development, reflecting the broad potential application of the company’s gene‑editing platform.
Later in 2025, RheumaGen also announced a Series A‑1 preferred stock investment from Beyond Celiac Investments, the venture philanthropy arm of Beyond Celiac, to support its celiac disease program. This investment is designed to advance the early development of RheumaGen’s HLA gene‑editing approach for celiac disease toward preclinical proof of concept, marking a significant step in translating the platform across varied autoimmune indications.
The backing from both traditional venture investors and disease‑focused venture philanthropy reflects a strategic blend of capital that supports both scientific rigor and patient impact. Beyond Celiac Investments’ participation highlights the promise seen in RheumaGen’s platform to address celiac disease — a condition lacking curative treatments — by leveraging the same underlying gene‑editing science applied in the company’s RA and broader autoimmunity efforts.
RheumaGen’s emergence and successful Series A financing represent a growing trend in biotechnology toward precision gene‑editing approaches that seek to cure diseases rather than manage symptoms. With the expanded funding, strategic investor support, and a pipeline targeting multiple autoimmune disorders, RheumaGen is positioned to advance its vision of transforming autoimmunity treatment through innovative genetic medicine.
